US Diabetes Devices Market size was valued at USD 6.8 Billion in 2024 and is expected to reach USD 19.8 Billion by 2033, at a CAGR of 7.3% during the forecast period 2024 – 2033.

US Diabetes Devices Market: Overview

Glucose monitoring systems, such as glucometers, help individuals measure their blood sugar levels, while CGM systems provide continuous real-time glucose readings, offering valuable insights into glucose trends and patterns. Insulin delivery devices, such as insulin pumps, pens, and syringes, enable precise administration of insulin doses to regulate blood sugar levels.

In the US, the diabetes device market is witnessing several prominent trends that are reshaping how diabetes is managed. Firstly, there’s a notable shift towards greater integration and connectivity in diabetes devices, driven by advancements in digital health technologies.

This includes the rise of continuous glucose monitoring (CGM) systems and insulin pumps with smartphone connectivity, allowing for real-time data monitoring and remote patient management. Secondly, there’s a growing emphasis on user-friendly and discreet designs, catering to the preferences and lifestyle needs of individuals with diabetes.

Additionally, there’s increasing interest in the development of closed-loop systems or artificial pancreas technologies, aiming to automate insulin delivery and optimize blood glucose control.

Furthermore, there’s a trend towards personalized medicine, with the integration of data analytics and artificial intelligence to tailor diabetes management strategies to individual patient characteristics, leading to more precise and effective treatment outcomes.

By type, the insulin delivery devices segment held the highest market share in 2023 and is expected to keep its dominance during the forecast period 2024-2033. The trend in insulin delivery devices is towards increased convenience, accuracy, and integration of technology.

This includes the development of smaller, more discreet insulin pumps, wearable continuous glucose monitors, and automated insulin delivery systems to improve management and quality of life for individuals with diabetes.

By application, the hospital pharmacies segment held the highest market share in 2023 and is expected to keep its dominance during the forecast period 2024-2033.

A growing trend in hospital pharmacies is the integration of advanced technologies such as automated medication dispensing systems, robotic medication compounding, and electronic health record integration. These innovations aim to enhance medication safety, efficiency, and patient care outcomes.

By end user, hospital segment held highest market share in 2023 and is expected to keep its dominance during the forecast period 2024-2033.

A notable trend in hospitals is the increasing integration of technology, such as telemedicine and remote monitoring systems, to enhance patient care delivery and efficiency. This shift reflects a broader emphasis on digital health solutions and patient-centered care models.

Becton Dickinson and Co (BD) is a medical technology company, which manufactures and sells medical devices, reagents, and instruments.

Report Scope

Feature of the ReportDetails
Market Size in 2024USD 6.8 Billion
Projected Market Size in 2033USD 19.8 Billion
Market Size in 2023USD 5.4 Billion
CAGR Growth Rate7.3% CAGR
Base Year2023
Forecast Period2024-2033
Key SegmentBy Type, Sale Channel, End User and Region
Report CoverageRevenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends
Regional ScopeUS
Buying OptionsRequest tailored purchasing options to fulfil your requirements for research.

CMI has comprehensively analyzed US Diabetes Devices market. The driving forces, restraints, challenges, opportunities, key trends have been explained in depth to depict in depth scenario of market. Segment wise market size and market share during the forecast period is duly addressed to portray the probable picture of this US Diabetes Devices  industry.

The competitive landscape includes of key innovators, after market service providers, market giants as well as niche players are studied and analyzed extensively with respect to their strengths, weaknesses as well as value addition prospects. In addition, this report covers key players profiling, market shares, mergers and acquisitions, consequent market fragmentation, new trends and dynamics in partnerships.

US Diabetes Devices Market 2024–2033 (By Billion)

www.custommarketinsight.com

List of the prominent players in the US Diabetes Devices Market:

  • Medtronic
  • Roche
  • Johnson & Johnson
  • Abbott Laboratories
  • Becton Dickinson and Company
  • Novo Nordisk
  • Dexcom
  • Sanofi
  • Insulet Corporation
  • Ascensia Diabetes Care Holdings AG
  • Ypsomed Holding AG
  • Eli Lilly and Company
  • LifeScan
  • Tandem Diabetes Care
  • Terumo Corporation
  • Arkray
  • Senseonics Holdings Inc.
  • MicroPort Scientific Corporation
  • Nipro Corporation
  • Sinocare Inc.
  • AgaMatrix Holdings LLC
  • Trividia Health Inc.
  • Others

The US Diabetes Devices Market is segmented as follows:

By Type

  • Blood Glucose Monitoring Devices
  • Insulin Delivery Devices

By Sale Channel

  • Hospital pharmacies
  • Retail Pharmacies
  • Diabetes Clinics
  • Online Pharmacies
  • Others

By End User

  • Hospitals
  • Diagnostic Center